Unknown
OBSERVATIONAL
NCT02673632
The Influence of AMH on Ovarian Responsiveness to Ovulation Induction With GnRH in Women With PCOS
View on ClinicalTrials.gov
Updated Dec 15, 2025
Brief Summary
The investigator suggests that PCOS women with high AMH levels are resistant to ovarian stimulation and may need adjustment of the dose of gonadotrophin.
Detailed Description
There is a correlation between high levels of AMH and the severity of PCOS. Excessive AMH may have a negative effect on the sensitivity of the resting follicles to gonadotropins. This is an observational prospective study to investigate the impact of circulating AMH on gonadotrophin induction in women with PCOS.
Interventions
Name:
Merional ®
Type:
DRUG
Description:
Using the long protocol of controlled ovarian hyperstimulation (COH). Down regulation by (Decapeptyl ®, Ferring) 0.1mg subcutaneously once daily starting from day 18 of the preceding cycle, human menopausal gonadotrophin (hMG) (Merional ®, IBSA) 75 IU starting from cycle day two after confirmation of down regulation (thin endometrium, number of follicular activity, E2 \< 50 pg/mL). hMG dose is optimized according to age, BMI, antral follicles count (AFC), the local protocol, FSH level and previous response. Usually PCO patients start by 150 IU.
Primary Outcomes
Measure:
Good response to hMG therapy defined as occurrence of > 3 mature follicles after treatment.
TimeFrame:
30 days
Description:
Good response to hMG therapy defined as occurrence of \> 3 mature follicles after treatment.
Trial Information
NCT ID
NCT02673632
Status
Unknown
Study Type
OBSERVATIONAL
Sponsor
Ain Shams Maternity Hospital
Last Updated
December 15, 2025